IOL Chemicals & Pharmaceuticals, a leading Active Pharmaceutical Ingredient (API) manufacturer, has reported strong financial results for the quarter and nine months ended 31 December 2025, driven by double-digit revenue growth and expanding margins.

 

The company’s profit before tax (PBT) before exceptional items surged 39% year-on-year in Q3 FY26, alongside a notable EBITDA increase of 22.8% and a margin expansion of 102 basis points. Revenue for the quarter rose to ₹580.4 crore, up 10.9% from ₹523.3 crore in Q3 FY25. For the nine months, revenue reached ₹1,699.6 crore, a 9.6% rise over the previous year.

 

Pharmaceuticals revenue jumped 18% YoY, increasing its share of overall revenue from 57% in Q3 FY25 to 61% in Q3 FY26. EBIT from the segment grew 32% YoY, supported by robust volume growth and strong traction in non-Ibuprofen APIs.

 

Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY.

 

Commenting on the performance, Vikas Gupta, Joint Managing Director, said: "Q3 FY26 has been a resilient quarter for IOL, marked by double-digit revenue growth, margin expansion, and a 39% YoY increase in profit before exceptional items and tax, despite prevailing geopolitical uncertainties. This performance underscores the resilience of our operations and sustained demand across our businesses.

 

"Our Pharmaceuticals segment continues to lead growth, delivering an 18% revenue increase year-on-year. Importantly, pharma’s share of overall revenue has risen from 57% in Q3 FY25 to 61% in Q3 FY26, highlighting its growing contribution. EBIT from Pharmaceuticals grew 32% YoY, driven by healthy volume growth and strong traction in non-Ibuprofen APIs, which are broadening and diversifying our product portfolio."

 

He added: "In Chemicals, we achieved optimal capacity utilisation, reflecting improved demand and operational discipline. EBIT grew 37% YoY, supported by efficiency gains and sustained customer traction. This validates the strength of our diversified business model and the meaningful contribution of both segments.

 

"Looking ahead, our focus remains on expanding our presence in regulated markets, strengthening our new product pipeline, deepening backward integration, and enhancing R&D capabilities. These measures will help us sustain growth momentum, enhance competitiveness, and deliver long-term value creation for our stakeholders.”